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Background
In Romania, the incidence of hepatocellular carcinoma
(HCC) has increased over the past ten years due to the
increasing number of cirrhotic patients (more than 90%
of the cases of HCC develop in cirrhosis). Antiviral
nucleos(t)ide analogues have been widely used to reduce
the development of HCC in chronic hepatitis B patients
with fibrosis or cirrhosis.
Methods
We included 36 patients with hepatitis B virus related
cirrhosis. Since February 2008 until now, 45%
(16 patients) were treated with lamivudine and 55%
(20 patients) with entecavir. The evaluation was per-
formed every 3-4 months by clinical exam, biochemical
and serological tests, and abdominal ultrasonography
for all patients. Upper endoscopy, computed tomogra-
phy scanning or magnetic resonance imaging were
done in selective cases.
Results
The median age at the diagnosis of cirrhosis was 57.6±10.7
years and 75% of patients were males. Six cases (16.66%)
were diagnosed with HCC – all of them were males.
Only one of these patients was treated with entecavir,
while the rest received lamivudine. Risk factors involved
in carcinogenesis were represented by: age over 60, male
gender, cirrhosis evolution for more than 5 years.
Conclusion
The results of this study suggested that the incidence of
HCC is lower in patients with HBV-related cirrhosis
who used entecavir (5%) compared to lamivudine (31%).
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